Aptinyx stung by pain drug’s mid-stage miss
Aptinyx, an Illinois-based biotech, saw its share value dive roughly 70% Wednesday morning after announcing its lead candidate failed a Phase 2 study of patients w...
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.